RT Journal Article
SR Electronic
T1 Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.26.20202283
DO 10.1101/2020.09.26.20202283
A1 López-Medrano, Francisco
A1 Pérez-Jacoiste Asín, María Asunción
A1 Fernández-Ruiz, Mario
A1 Carretero, Octavio
A1 Lalueza, Antonio
A1 de la Calle, Guillermo Maestro
A1 Caro, José Manuel
A1 de la Calle, Cristina
A1 Catalán, Mercedes
A1 García-García, Rocío
A1 Martínez-López, Joaquín
A1 Origüen, Julia
A1 Ripoll, Mar
A1 Juan, Rafael San
A1 Trujillo, Hernando
A1 Sevillano, Ángel
A1 Gutiérrez, Eduardo
A1 de Miguel, Borja
A1 Aguilar, Fernando
A1 Gómez, Carlos
A1 Silva, José Tiago
A1 de Morales, Daniel García-Ruiz
A1 Saro-Buendía, Miguel
A1 Marrero-Sánchez, Ángel
A1 Chiara-Graciani, Guillermo
A1 Bueno, Héctor
A1 Paz-Artal, Estela
A1 Lumbreras, Carlos
A1 Pablos, José L.
A1 Aguado, José María
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.26.20202283.abstract
AB Background The role of combination immunomodulatory therapy with systemic corticosteroids and tocilizumab (TCZ) for aged patients with COVID-19-associated cytokine release syndrome remains unclear.Methods We conducted a retrospective single-center study including consecutive patients ≥65 years that developed severe COVID-19 between March 3 and May 1, 2020 and were treated with corticosteroids at various doses (methylprednisolone [0.5 mg/Kg/12 hours to 250 mg/24 hours]), either alone (“CS group”) or associated to intravenous tocilizumab (400-600 mg, one to three doses) (“CS-TCZ group”). Primary outcome was all-cause mortality by day +14, whereas secondary outcomes included mortality by day +28 and clinical improvement (discharge and/or a ≥2-point decrease on a six-point ordinal scale) by day +14. Propensity score (PS)-based adjustment and inverse probability of treatment weights (IPTW) were applied.Results Overall, 181 and 80 patients were included in the CS and CS-TCZ groups. All-cause 14-day mortality was lower in the CS-TCZ group, both in the PS-adjusted (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.17 – 0.68; P-value = 0.002) and IPTW-weighted models (odds ratio [OR]: 0.38; 95% CI: 0.21 – 0.68; P-value = 0.001). This protective effect was also observed for 28-day mortality (PS-adjusted HR: 0.38; 95% CI: 0.21 – 0.72; P-value = 0.003). Clinical improvement by day +14 was higher in the CS-TCZ group in the IPTW analysis only (OR: 2.26; 95% CI: 1.49 – 3.41; P-value <0.001). The occurrence of secondary infection was similar between both groups.Conclusions The combination of corticosteroids and TCZ was associated with better outcomes among patients ≥65 years with severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 call COV20/00181) co-financed by European Development Regional Fund A way to achieve Europe. M.F.R. holds a research contract Miguel Servet (CP 18/00073) from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Investigacion Clinica CEIC Instituto de Investigacion i+12 Hospital Universitario 12 de Octubre Madrid SpainAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable under request